Abstract
Objective: To determine the pharmacokinetics and pharmacodynamics of the neuromoscular blocking agent atracurium besylate in patients with fulminant hepatic failure (FHF).
Design: Open study of patients receiving atracurium infusions to facilitate mechanical ventilation.
Setting: Intensive care unit in a tertiary referral university teaching hospital.
Patients: Ten encephalopathic patients with FHF reuiring mechanical ventilation while awaiting orthotopic liver transplantation. Three patients died before transplantation could be performed, three died after transplantation, and four survived following successful transplantation.
Methods: Plasma, urine and dialysate fluid were analysed for atracurium and its metabolites using HPLC. Neuromuscular blockade was measured using transcutmeous ulnar nerve stimulation and an accelerometer. Electroencephalography and liver function tests were performed daily.
Results: Patients received atracurium infusions for a period ranging from 38 to 217 h. Six patients required continuous arteriovenous haemodiafiltration (CAVHD) to replace renal function. Atracurium mean steady state clearence was 8.6 ml/min/kg, and train-of-four recovery ratio, to 75% took 63 min (range 32–108). Laudanosine clearance was markedly reduced in the non-survivors; the half-life was 38.5 hrs compared with 5.3 h in the 4 patients who underwent successful transplantation. Laudanosine accumulation could be observed in all patients before transplantation, but kinetics returned to normal after successful transplantation. The highest laudanosine level recorded was 6,860 ng/ml. There was no evidence of adverse central neurological effects attributable to laudanosine. CAVHD did not contribute significantly to clearance of atracurium or its metabolites.
Conclusions: Atracurium kinetics and dynamics are nearnormal even in patients with fulminant hepatic failure and renal failure; laudanosine accumulation will occur, but this is not associated with measurable central neurological effects. Implantation of a functioning liver graft results in clearance of laudanosine, which seems to be independent of renal function. Atracurium is an appropriate choice for producing neuromuscular blockade for periods of several days in patients with fulminant hepatic failure and renal impairment.
Similar content being viewed by others
References
Waterton C (1878) Wanderings in South America. Macmillan, London
Miller-Jones CMH, Williams JH (1980) Sedation for ventilation. A retrospective study of fifty patients. Anaesthesia 35: 1104–1107
Bion JF, Ledingham IMcA (1987) Sedation in intensive care — a postal survey. Intensive Care Med 13:215–216
Chapple DJ, Miller AA, Ward JB, Wheatley PL (1987) Cardiovascular and neurological effects of laudanosine. Studies in mice and rats, and in conscious and anaesthetised dogs. Br J Anaesth 59: 218–225
Ingram MD, Sclabassi RJ, Stiller RL, Cook DR, Bennett MH (1985) Cardiovascular and electroencephalographic effects of laudanosine in ‘nephrectomised” cats. Anesth Analg 64: 232
Simmonds RJ (1985) Determination of atracurium, laudanosine and related compounds in plasma by high performance liquid chromatography. J Chromatogr 343: 431–436
Fahey MR, Rupp SM, Fisher DM et al (1984) The pharmacokinetics and pharmacodynamics of atracurium in patients with and without renal failure. Anesthesiology 61: 699–702
Yate PM, Flynn PJ, Arnold RW, Weatherley BC, Simmonds RJ, Dopson T (1987) Clinical experience and plasma laudanosine concentrations during the infusion of atracurium in the intensive therapy unit. Br J Anaesth 59: 211–217
Parker CJR, Jones JE, Hunter JM (1986) Atracurium infusions in patients with renal failure on an ITU. Anaesthesia 41: 375–381
Marston A, Bulkley GB, Fiddian-Green RG, Haglund UH (eds) (1989) Splanchnic Ischaemia and Multiple Organ Failure. Edward Arnold, London
Shearer ES, O'Sullivan EP, Hunter JM (1991) Clearance of atracurium and laudanosine in the urine and by continuous venovenous haemofiltration. Br J Anaesth 67:569–573
Beemer GH, Bjorksten AR, Crankshaw DP (1989) Pharmacokinetics of atracurium during continuous infusion. Br J Anaesth 63: 661–666
Gwinnutt CL, Eddleston JM, Edwards D, Pollard BJ (1990) Concentrations of atracurium and laudanosine in cerebrospinal fluid in three intensive care patients. Br J Anaesth 65:829–832
Ward S, Neill EAM (1983) Pharmacokinetics of atracurium in acute hepatic failure (with acute renal failure). Br J Anaesth 55: 1169–1172
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Bion, J.F., Bowden, M.I., Chow, B. et al. Atracurium infusions in patients with fulminant hepatic failure awaiting liver transplantation. Intensive Care Med 19 (Suppl 2), S94–S98 (1993). https://doi.org/10.1007/BF01708809
Issue Date:
DOI: https://doi.org/10.1007/BF01708809